Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial
Chiara Nicolazzo(Sapienza University of Rome), Cristina Raimondi(Sapienza University of Rome), Flavia Loreni(Sapienza University of Rome), Paola Gazzaniga(Sapienza University of Rome), Gian Maria Busetto(Sapienza University of Rome), Isabella Sperduti(San Gallicano Hospital), Angela Gradilone(Sapienza University of Rome), Enrico Cortesi(Sapienza University of Rome), Francesco Del Giudice(Sapienza University of Rome), Ettore De Berardinis(Policlinico Umberto I)
Cited by 54
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility
|The World Journal of Men s Health|2019|468
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
|British Journal of Cancer|2020|350
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268